Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis

Share this content:
Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis
Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis
In a randomized controlled trial, liraglutide met the primary endpoint of histological clearance of non-alcoholic steatohepatitis, and a reduction in progression of fibrosis A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented at The International Liver CongressTM 2015.
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




is free, fast, and customized just for you!




Already a member?

Sign In Now »